Characteristics and Outcomes of @entity2883 With XXXX (Wegener) and Microscopic Polyangiitis Requiring Renal Replacement Therapy: Results From the European Renal Association-European Dialysis and Transplant Association Registry.

@entity1 @entity8 @entity6 @entity1333 @entity177 @entity2883 @entity631 @entity204 @entity21481
BACKGROUND: This study describes the incidence and outcomes of European @entity1 requiring renal replacement therapy (RRT) for @entity177 due to antineutrophil cytoplasmic antibody (ANCA)-associated @entity1333 (AAV). STUDY DESIGN: Cohort study. SETTING _ @entity1 : 12 renal registries providing individual RRT @entity1 data to the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry in 1993-2012 participated. PREDICTOR: Cause of primary @entity8 : AAV (ie, @entity2883 with @entity2883 [Wegener] and microscopic @entity2883 ) versus 3 separate matched control groups without @entity21481 ) primary @entity631 , (2) @entity6 , and (3) disease other than @entity6 as the cause of primary @entity8 , including @entity631 (termed "nondiabetes"). OUTCOMES: Incidence, causes of @entity204 , and survival. MEASUREMENTS: ERA-EDTA primary @entity8 codes. RESULTS: 2,511 @entity1 with @entity21481 ,755, @entity2883 with @entity2883 ; 756, microscopic @entity2883 ) were identified, representing an incidence of 1.05 per million population (pmp) for @entity2883 with @entity2883 (predominating in Northern Europe) and 0.45 pmp for microscopic @entity2883 (prevailing in Southern Europe). Kidney transplantation was performed in 558 (22.2%) @entity1 with @entity1333 . The 10-year probability for survival on RRT after day 91 was 32.5% (95% CI, 29.9%-35.1%) in @entity1 with @entity1333 . Survival on RRT after day 91 did not differ between AAV and matched nondiabetes @entity1 . @entity1 and transplant survival after kidney transplantation, adjusted for time period and country, was better in AAV than in matched nondiabetes @entity1 (HRs of 0.81 [95% CI, 0.67-0.99] and 0.82 [95% CI, 0.69-0.96], respectively). LIMITATIONS: No data for extrarenal manifestations, treatment, and relapses. CONCLUSIONS: Geographical differences in the incidence of RRT for @entity177 due to @entity2883 with @entity2883 and microscopic @entity2883 copied their distribution in the general population. Overall survival on RRT after day 91 for @entity1 with AAV was similar to that for @entity1 with nondiabetes diagnoses. Our results suggest that @entity1 with AAV are suitable candidates for kidney transplantation with favorable survival outcomes.
